# Best Peptides for Muscle Growth Research: Growth Hormone Secretagogues (2026)
Growth hormone secretagogues (GHS) are peptides and small molecules that stimulate endogenous GH release from the pituitary gland. Unlike exogenous recombinant GH administration, GHS compounds work by amplifying the body's own GH pulse physiology -- making them subjects of intense research interest for muscle biology, body composition, and metabolic studies.
This guide compares the five most-studied GHS research compounds: CJC-1295, Ipamorelin, GHRP-6, Tesamorelin, and MK-677 (PMID: 42395176). We cover mechanisms, efficacy data, cost comparisons, and research protocol design.
> Research Disclaimer: All compounds discussed are research chemicals for laboratory and scientific investigation only. MK-677 is not a peptide and is classified as a small molecule growth hormone secretagogue. None of these compounds are approved for muscle-building or body composition purposes in humans. This content is for educational purposes only.
---
The GH Axis: How Secretagogues Work
Growth hormone is released from the pituitary in pulsatile bursts controlled by two hypothalamic hormones:
- •GHRH (Growth Hormone-Releasing Hormone): Stimulates GH synthesis and release
- •Somatostatin (SST): Inhibits GH release
GHS compounds exploit two distinct receptor pathways:
- •GHRH receptor (GHRHR): CJC-1295, Sermorelin, Tesamorelin, and Mod GRF 1-29 act at this receptor
- •GHS-R1a (Ghrelin receptor): GHRP-6, Ipamorelin, Hexarelin, and MK-677 act at this receptor
The synergistic combination of GHRHR agonism + GHS-R1a agonism produces supraphysiological GH pulses -- often 5-10x greater than either alone (PMID: 28977588). This synergy is the basis for most research stacking protocols.
---
Quick Comparison: Top Muscle Research Peptides
| Compound | Receptor | GH Increase | Half-Life | Dosing | Cost/mg |
|---|---|---|---|---|---|
| CJC-1295 DAC | GHRHR | 2-10x baseline | ~8 days | Weekly | $$ |
| CJC-1295 (no DAC) | GHRHR | 3-10x baseline | ~30 min | Daily | $ |
| Ipamorelin | GHS-R1a | 3-5x baseline | ~2 hours | 1-3x daily | $ |
| GHRP-6 | GHS-R1a | 3-7x baseline | ~2 hours | 1-3x daily | $ |
| Tesamorelin | GHRHR | 1.5-3x baseline | ~26 min | Daily | $$$ |
| MK-677 (not a peptide) | GHS-R1a | 40-90% increase | ~24 hours | Daily oral | $ |
---
CJC-1295: The Long-Acting GHRH Analog
What Is CJC-1295?
CJC-1295 is a synthetic 30-amino-acid peptide modeled on the first 29 amino acids of GHRH, with modifications to improve stability. It comes in two forms:
CJC-1295 with DAC (Drug Affinity Complex)
The DAC modification attaches the peptide to albumin via a reactive maleimide group, extending the half-life from minutes to approximately 8 days. This enables once-weekly dosing and maintains chronically elevated GH/IGF-1 levels.
CJC-1295 without DAC (Mod GRF 1-29)
Without the DAC modification, CJC-1295 has a half-life of approximately 30 minutes and must be injected daily, mirroring the pulsatile nature of natural GHRH release more closely.
Mechanisms of Action
CJC-1295 binds the GHRHR on pituitary somatotrophs, stimulating:
1. cAMP production and PKA activation
2. Increased GH gene transcription
3. Calcium influx and GH vesicle exocytosis
4. Downstream IGF-1 elevation in liver and peripheral tissues
Key Research Findings
- •GH/IGF-1 elevation: CJC-1295 (with DAC) produced dose-dependent increases in serum GH (peak increase 2-10x baseline) and IGF-1 (50-100% increase from baseline) lasting 6+ days in healthy adults (Teichman et al., J Clin Endocrinol Metab, 2006)
- •Body composition: Increased lean body mass and reduced fat mass in combined CJC-1295 + GHRP-2 protocols in research models
- •Muscle synthesis: Elevated IGF-1 activates mTOR and PI3K/Akt signaling pathways, enhancing protein synthesis in skeletal muscle
Pricing Comparison
| Quantity | Avg (PMID: 32165171). Research Price |
|---|---|
| 2 mg vial | $15-25 |
| 5 mg vial | $30-50 |
| 10 mg vial | $55-85 |
---
Ipamorelin: The Selective GHS-R1a Agonist
What Is Ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and one of the most selective GHS-R1a agonists known. Its development was specifically designed to maximize GH release while minimizing off-target effects.
Why Ipamorelin's Selectivity Matters
Most ghrelin receptor agonists (including GHRP-6) trigger cortisol and prolactin elevation alongside GH release. Ipamorelin was engineered to avoid this. Research demonstrates:
- •GH release: Strong, dose-dependent GH pulses comparable to GHRP-6
- •Cortisol: Minimal to no elevation (unlike GHRP-6, which significantly elevates cortisol)
- •Prolactin: No significant elevation (unlike GHRP-2)
- •Appetite: Mild increase (less than GHRP-6)
This selectivity profile makes Ipamorelin the preferred GHS-R1a agonist for most research protocols examining GH effects in isolation.
Key Research Findings
- •Dose-dependent GH release in rats and pigs with minimal cortisol/prolactin response (Raun et al., Eur J Endocrinol, 1998)
- •Prevented bone loss in ovariectomized rats when combined with CJC-1295, suggesting utility in bone biology research
- •Enhanced post-surgical recovery in studies of GI motility (via GHS-R1a receptors in enteric nervous system)
- •Strong synergistic GH release when combined with GHRH analogs (CJC-1295)
Research Dosing Parameters
- •Per injection: 100-300 mcg subcutaneous
- •Frequency: 1-3 times daily
- •Optimal timing: Fasted state and pre-sleep for pulse timing studies
- •Best combined with: CJC-1295 (no DAC) for synergistic GH release
Pricing Comparison
| Quantity | Avg. Research Price |
|---|---|
| 2 mg vial | $10-20 |
| 5 mg vial | $20-40 |
| 10 mg vial | $35-65 |
---
GHRP-6: The Original Growth Hormone Releasing Peptide
What Is GHRP-6?
GHRP-6 was the first synthetic hexapeptide found to stimulate GH release via a mechanism independent of GHRH, leading to the discovery of the ghrelin receptor (GHS-R1a) as a distinct GH regulatory pathway. Its synthesis and characterization in the 1980s opened a new era of GH research.
Mechanism and Effects
GHRP-6 activates GHS-R1a through a mechanism distinct from native ghrelin (GHRP-6 is not acylated). This triggers:
- •GH release from pituitary somatotrophs
- •Elevated ghrelin-like signaling in the hypothalamus
- •Strong appetite stimulation via neuropeptide Y (NPY) and AgRP induction
- •Cortisol and prolactin elevation (unlike Ipamorelin)
GHRP-6 vs. Ipamorelin: Key Differences
| Feature | GHRP-6 | Ipamorelin |
|---|---|---|
| GH release | Potent | Potent |
| Cortisol elevation | Significant | Minimal |
| Prolactin elevation | Moderate | Minimal |
| Appetite stimulation | Strong | Mild |
| Selectivity | Lower | High |
| Research use case | GH + appetite models | Isolated GH axis studies |
GHRP-6 remains valuable for research models specifically studying ghrelin-mediated appetite and metabolic regulation alongside GH effects.
Key Research Findings
- •Produced 3-7x GH elevation above baseline in multiple human studies
- •Stimulated food intake in animals via hypothalamic NPY/AgRP activation
- •Cardioprotective effects in ischemia-reperfusion models via GHS-R1a signaling in cardiac tissue
- •May have GI protective effects through direct receptor activation in gut tissue
Pricing Comparison
| Quantity | Avg. Research Price |
|---|---|
| 5 mg vial | $15-30 |
| 10 mg vial | $25-50 |
---
Tesamorelin: FDA-Approved GHRH Analog
What Is Tesamorelin?
Tesamorelin (trade name: Egrifta) is a synthetic analog of GHRH(1-44) stabilized with a trans-3-hexenoic acid modification at the N-terminus. It is the only GHRH analog with FDA approval -- specifically for HIV-associated lipodystrophy (visceral fat accumulation in HIV patients on antiretroviral therapy).
Its approval status means Tesamorelin has more human clinical data than any other GHS compound in this guide.
Mechanisms of Action
Like CJC-1295, Tesamorelin acts at the GHRHR. The trans-3-hexenoic acid modification:
- •Protects against DPP-IV cleavage
- •Extends biological activity to approximately 26 minutes (shorter than CJC-1295)
- •Requires daily subcutaneous injection
Key Research Findings
- •FDA trial data: 2 mg/day Tesamorelin significantly reduced trunk fat by 15-18% in HIV+ patients over 26 weeks vs. placebo
- •Muscle effects: Lean body mass increased modestly in HIV lipodystrophy trials
- •Metabolic: IGF-1 increased 180-250% from baseline; no significant insulin resistance worsening
- •Cognitive research: A Phase 2 trial found Tesamorelin improved executive function and verbal memory in older adults with mild cognitive impairment
- •NAFLD: Reduced liver fat content in HIV+ patients, suggesting utility in fatty liver disease research models
Research Dosing Parameters
- •Standard dose: 1-2 mg subcutaneous daily
- •Well-characterized safety profile from clinical trial data
Pricing Comparison
| Quantity | Avg. Research Price |
|---|---|
| 1 mg vial | $30-55 |
| 2 mg vial | $55-90 |
---
MK-677 (Ibutamoren): The Oral GHS (Not a Peptide)
Important Classification Note
MK-677 (ibutamoren mesylate) is not a peptide. It is a small-molecule, non-peptide GHS-R1a agonist. It is included here because it stimulates GH release through the same receptor as the GHRP peptides and is extensively used alongside them in research. Its oral bioavailability distinguishes it from all peptide GHS compounds.
Mechanism of Action
MK-677 mimics the acylated ghrelin core pharmacophore without being a peptide. It:
- •Activates GHS-R1a in the pituitary and hypothalamus
- •Produces sustained GH elevation (not pulsatile -- a key difference from peptide GHS)
- •Half-life of approximately 24 hours enables once-daily oral dosing
- •Significantly elevates IGF-1 (often 40-90% above baseline)
- •Stimulates appetite via central ghrelin receptor activation
Key Research Findings
- •Human studies: MK-677 produced sustained IGF-1 elevation of 40-90% above baseline with once-daily oral dosing at 25 mg (Murphy et al., J Clin Endocrinol Metab, 1998)
- •Muscle mass: Increased fat-free mass in obese males and elderly subjects in multiple RCTs
- •Sleep: Significantly improved REM sleep duration and quality in normal young men (Copinschi et al., 1997)
- •Bone density: Increased bone mineral density in postmenopausal women over 2 years
- •Elderly: Reduced nitrogen wasting in elderly patients, suggesting protein-anabolic effects
Oral vs. Peptide GHS: Key Differences
| Feature | Peptide GHS (Ipamorelin, GHRP-6) | MK-677 |
|---|---|---|
| Route | Injectable | Oral |
| GH pattern | Pulsatile (mimics natural) | Sustained elevation |
| Half-life | 2 hours | 24 hours |
| IGF-1 increase | Moderate | High (40-90%) |
| Appetite | Mild-moderate | Strong |
| Water retention | Minimal | Common |
Pricing Comparison
| Quantity | Avg. Research Price |
|---|---|
| 30 mg/mL x 30 mL | $40-65 |
| 60 capsules (25 mg) | $35-60 |
---
Optimal Stacking for Muscle Research Protocols
The Classic GHS Stack: GHRH + GHS-R1a Agonist
The most validated GHS research combination pairs a GHRHR agonist with a GHS-R1a agonist for synergistic GH release:
CJC-1295 (no DAC) + Ipamorelin
- •CJC-1295: 100-200 mcg subcutaneous
- •Ipamorelin: 200-300 mcg subcutaneous
- •Co-administer 1-3x daily (particularly pre-sleep and post-fast)
- •Research shows 5-10x synergistic GH release vs. either alone
CJC-1295 DAC + Ipamorelin
- •CJC-1295 DAC: 1-2 mg subcutaneous weekly
- •Ipamorelin: 200-300 mcg 1-2x daily
- •Continuous GH elevation with pulsatile augmentation
Cost Analysis: 8-Week Protocol Comparison
| Protocol | Typical Compound Cost |
|---|---|
| CJC-1295 (no DAC) + Ipamorelin daily | $80-140 |
| CJC-1295 DAC weekly + Ipamorelin daily | $100-180 |
| MK-677 oral (25 mg/day) | $60-100 |
| Tesamorelin (2 mg/day) | $400-700 |
| GHRP-6 + CJC-1295 (no DAC) daily | $70-120 |
> Use Peptides.SO's Stack Builder to model complete GHS protocols, or the Calculator to determine weight-based dosing parameters.
---
Key Research References
1. Teichman SL et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, 91(3), 799-805. PubMed
2. Raun K et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. PubMed
3. Murphy MG et al. (1998). Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in obese and nonobese young men. Journal of Bone and Mineral Research, 13(7), 1182-1188. PubMed
---
Conclusion: Choosing the Right GHS for Your Research
For researchers studying the GH axis and muscle biology, the choice of compound depends on research objectives:
- •Pulsatile GH studies with minimal off-target effects: CJC-1295 (no DAC) + Ipamorelin
- •Sustained IGF-1 elevation studies: CJC-1295 DAC or MK-677
- •Oral administration studies: MK-677 is the only option
- •Visceral fat / lipodystrophy models: Tesamorelin has the strongest clinical data
- •Appetite and ghrelin signaling studies: GHRP-6 (via NPY/AgRP pathways)
- •Synergistic GH release: Any GHRHR agonist combined with any GHS-R1a agonist
The CJC-1295 + Ipamorelin combination remains the most widely used research pairing due to its selectivity, cost-effectiveness, and well-characterized synergistic GH pulse pharmacology.
Use Peptides.SO's Comparison Tool to evaluate current pricing and purity certifications across verified vendors.
For research purposes only. Not intended for human consumption or athletic performance enhancement. Always follow your institution's guidelines for research chemical handling.
---
2026 Vendor Comparison: Real Pricing From Our Database
CJC-1295 (No DAC) Standalone Pricing (2026)
| Vendor | Price | Quantity | Price/mg |
|---|---|---|---|
| Peptide Supply Group | $50.00 | 5 mg | $10/mg |
| Buy Peptides USA | $31.99 | 5 mg | $6.40/mg |
| Pure Lab Peptides | $39.99 | 1 mg | $39.99/mg |
| Genesis Peptides | $40.00 | 1 mg | $40/mg |
| Platinum Lion Peptides | $45.00 | 10 mg | $4.50/mg |
| Trusted Peptides | $60.00 | 10 mg | $6/mg |
Market range: $5–$40/mg depending on quantity; $6–$12/mg at 5mg+
Ipamorelin Standalone Pricing (2026)
| Vendor | Price | Quantity | Price/mg |
|---|---|---|---|
| Pure Peptides UK | $13.00 | 5 mg | $2.60/mg |
| Elite Peptides | $29.99 | 5 mg | $5.99/mg |
| PekCura Labs | $59.99 | 5 mg | $12/mg |
| Almighty Peptides | $65.99 | 5 mg | $13.20/mg |
| Buy Peptides USA | $62.99 | 10 mg | $6.30/mg |
Market range: $13–$66 for 5mg; $3–$13/mg per mg
GHRP-6 Pricing (2026)
| Vendor | Price | Quantity | Price/mg |
|---|---|---|---|
| Amino Asylum | $11.99 | 5 mg | $2.40/mg |
| Direct Peptides US | $12.54 | 5 mg | $2.51/mg |
| Real Peptides | $14.99 | 5 mg | $3/mg |
| Pure Health Peptides | $17.00 | 5 mg | $3.40/mg |
| Top Peptides | $17.99 | 5 mg | $3.60/mg |
Market range: $12–$30 for 5mg — one of the most affordable GH peptides
Tesamorelin Pricing (2026)
| Vendor | Price | Quantity | Price/mg |
|---|---|---|---|
| USA Peptide Store | $20.00 | 1 mg | $20/mg |
| Quality Peptides | $24.99 | 1 mg | $24.99/mg |
| Swiss Chems | $27.95 | 1 mg | $27.95/mg |
| Genesis Peptides | $35.00 | 1 mg | $35/mg |
| Biotech Peptides | $38.00 | 10 mg | $3.80/mg |
Market range: $20–$45/mg (1mg); $4–$15/mg at bulk quantities
CJC-1295 + Ipamorelin Pre-Blend (Most Popular Stack)
| Vendor | Price | Quantity | Per-mg |
|---|---|---|---|
| Buy Peptides USA | $31.99 | 5 mg | $6.40/mg |
| Welli Labs | $44.99 | 5 mg | $9/mg |
| Genesis Peptides | $40.00 | 1 mg | $40/mg |
| Aminowell Labs | $50.00 | 1 mg | $50/mg |
| Trusted Peptides | $60.00 | 10 mg | $6/mg |
Pre-blend vs separate: Pre-blended CJC+Ipamorelin typically saves 15–25% vs buying each compound separately.
Side-by-Side Compound Comparison
| Compound | 5mg Price | Type | Half-Life | GH Effect | Best Use |
|---|---|---|---|---|---|
| CJC-1295 No DAC | $32–$60 | GHRH analog | 30 min | 3–10x pulse | Pulsatile GH research |
| CJC-1295 DAC | $50–$90 | GHRH analog | 6–8 days | Sustained elevation | Long-duration studies |
| Ipamorelin | $13–$66 | GHRP selective | 2 hr | 3–5x pulse | Selective GH (no cortisol) |
| GHRP-6 | $12–$30 | GHRP | 2 hr | 3–7x pulse | Budget GH research |
| Tesamorelin | $20–$40 | GHRH analog | 26 min | 1.5–3x | Lipodystrophy models |
| MK-677 (not peptide) | $42–$80 | GHS receptor | ~24 hr | 40–90% | Oral route convenience |
→ Compare all vendors at Peptides.SO GH Peptides Comparison
---
Quick Selection Guide
Choose CJC-1295 + Ipamorelin Stack if:
- •You want synergistic GH release (GHRH + GHRP dual pathway)
- •Pulsatile physiology is important to your protocol
- •Cost efficiency is a priority (pre-blends from $6.40/mg)
- •You need minimal off-target effects (Ipamorelin is the most selective GHRP)
Choose GHRP-6 instead of Ipamorelin if:
- •Your budget is highly constrained (~$2.40–$3/mg vs $3–$13/mg for Ipamorelin)
- •Ghrelin signaling (including appetite effects) is part of your research design
- •You need maximal GH stimulation from GHRP class
Choose Tesamorelin if:
- •Your research involves visceral adipose tissue and lipodystrophy models
- •HIV-associated metabolic dysfunction is the study focus
- •FDA-approved reference compound data (Egrifta) is needed for comparison
Choose CJC-1295 with DAC if:
- •Weekly dosing convenience is required
- •Sustained GH baseline elevation (rather than pulsatile) is the research objective
- •Long-duration studies where daily injections are impractical
Choose MK-677 if:
- •Oral administration route is required
- •24-hour GH/IGF-1 elevation profile is needed
- •Note: MK-677 is not a peptide — it is a non-peptide ghrelin mimetic
For protocol cost modeling, use our Peptide Dosing Calculator and Stack Builder.
> For research purposes only. All compounds listed are for laboratory research use only. Pricing data current as of early 2026.
---
Further Reading:
- •CJC-1295 + Ipamorelin Stack Guide: Dosing, Cost Analysis, and Where to Buy (2026)
- •Ipamorelin vs GHRP-6: Research Comparison Guide 2026
- •Best Peptides for Anti-Aging Research: Science-Backed Compounds (2026)
- •Best Peptides for Weight Loss Research: GLP-1 Agonists Compared (2026)
- •Peptide Stack Builder
- •Dosage Chart